Thomas Hoang
Neurology · New York, NYNPI 1912090598
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 286 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 54.2% of the total. Reporting peaked in 2024 at $2,300 and has fallen 94.6% since, to $125 in 2025.
Across 286 payments — averaging $27.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Lundbeck LLC$686
- Amgen$452
- Teva Pharmaceuticals USA, Inc.$377
- Neurocrine Biosciences, Inc.$327
- Pfizer$300
- plus $1K from 21 others
What the payments were for
- Speaking & faculty fees$3454%
- Food & beverage$7,43296%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 142 | $4,215 |
| Lundbeck LLC | 29 | $686 |
| Amgen | 14 | $452 |
| Teva Pharmaceuticals USA, Inc. | 9 | $377 |
| Neurocrine Biosciences, Inc. | 7 | $327 |
| Pfizer | 15 | $300 |
| Lilly USA, LLC | 12 | $294 |
| Biohaven Pharmaceuticals, Inc. | 18 | $220 |
| Novartis | 8 | $176 |
| Argenx US, Inc. | 1 | $118 |
| Eisai Inc. | 4 | $79 |
| Bausch Health US, LLC | 3 | $58 |
| Currax Pharmaceuticals LLC | 3 | $52 |
| Strongbridge US Inc. | 2 | $46 |
| Tonix Medicines, Inc. | 2 | $41 |
| Sanofi | 2 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| GE HealthCare | 2 | $36 |
| Medtronic | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Akcea Therapeutics, Inc. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| Genentech USA, Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Biogen | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,777 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.